Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Braz. j. med. biol. res ; 38(4): 597-602, Apr. 2005. graf
Artigo em Inglês | LILACS | ID: lil-398175

RESUMO

The objective of the present study was to assess the role of the 5-HT2A/2C receptor at two specific brain sites, i.e., the dorsal periaqueductal gray matter (DPAG) and the medial septal (MS) area, in maternal aggressive behavior after the microinjection of either a 5-HT2A/2C receptor agonist or antagonist. Female Wistar rats were microinjected on the 7th postpartum day with the selective agonist alpha-methyl-5-hydroxytryptamine maleate (5-HT2A/2C) or the antagonist 5-HT2A/2C, ketanserin. The agonist was injected into the DPAG at 0.2 (N = 9), 0.5 (N = 10), and 1.0 æg/0.2 æl (N = 9), and the antagonist was injected at 1.0 æg/0.2 æl (N = 9). The agonist was injected into the medial septal area (MS) at 0.2 (N = 9), 0.5 (N = 7), and 1.0 æg/0.2 æl (N = 6) and the antagonist was injected at 1.0 æg/0.2 æl (N = 5). For the control, saline was injected into the DPAG (N = 7) and the MS (N = 12). Both areas are related to aggressive behavior and contain a high density of 5-HT receptors. Non-aggressive behaviors such as horizontal locomotion (walking) and social investigation and aggressive behaviors such as lateral threat (aggressive posture), attacks (frontal and lateral), and biting the intruder were analyzed when a male intruder was placed into the female resident's cage. For each brain area studied, the frequency of the behaviors was compared among the various treatments by analysis of variance. The results showed a decrease in maternal aggressive behavior (number of bites directed at the intruder) after microinjection of the agonist at 0.2 and 1.0 æg/0.2 æl (1.6 ± 0.7 and 0.9 ± 0.3) into the DPAG compared to the saline group (5.5 ± 1.1). There was no dose-response relationship with the agonist. The present findings suggest that the 5-HT2A/2C receptor agonist has an inhibitory effect on maternal aggressive behavior when microinjected into the DPAG and no effect when microinjected into the MS. Ketanserin (1.0 æg/0.2 æl) decreased locomotion when microinjected into the DPAG and MS, but did not affect aggressive behavior. We interpret these findings as evidence for a specific role of 5-HT2A/2C receptors in the DPAG in the inhibition of female aggressive behavior, dissociated from those on motor activity.


Assuntos
Animais , Feminino , Masculino , Gravidez , Ratos , Agressão/efeitos dos fármacos , Ketanserina/farmacologia , Comportamento Materno/efeitos dos fármacos , Agonistas do Receptor de Serotonina/farmacologia , Antagonistas da Serotonina/farmacologia , Serotonina/análogos & derivados , Animais Recém-Nascidos , Ketanserina/administração & dosagem , Microinjeções , Substância Cinzenta Periaquedutal/efeitos dos fármacos , Ratos Wistar , /agonistas , /antagonistas & inibidores , /agonistas , /antagonistas & inibidores , Septo do Cérebro/efeitos dos fármacos , Agonistas do Receptor de Serotonina/administração & dosagem , Antagonistas da Serotonina/administração & dosagem , Serotonina/administração & dosagem , Serotonina/farmacologia
2.
Braz. j. med. biol. res ; 23(10): 1005-8, 1990. ilus
Artigo em Inglês | LILACS | ID: lil-91641

RESUMO

Male adult Schistosoma mansoni worms were placed in a glass dish containing Tyrode solution and observed for 15 min after addition of praziquantel (0.01 to 1 pmicron M). Praziquantel promoted a concentrationp- and time-dependent inhibition of sucker-mediated attachment of the worm. Attachment inhibition was correlated with shortening of the parasite. We propose that the rapid and total inhibition of worm attachment observed in vitro with 1 micronM praziquantel indicates that therapeutic concentrations of this drug should promote a rapid hepatic shift, in vivo, which may facilitate host tissue reaction


Assuntos
Animais , Técnicas In Vitro , Praziquantel/farmacologia , Schistosoma mansoni/fisiologia , Soluções Isotônicas , Contração Muscular/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA